On 17 February, primary results from a Phase IIb clinical trial assessing the...
- AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
- Blood and urine tests detect autism in children
- AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
- AAD 2018: AbbVie’s risankizumab boasts strong Phase III data in psoriasis
- NHS staff shortages could lead to cutbacks in clinical trials
AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
On 17 February, primary results from a Phase IIb clinical trial assessing the use of AbbVie’s upadacitinib in adult patients with moderate to severe atopic dermatitis (AD) was presented at the 76th Annual American Academy of Dermatology (AAD) meeting.
Phase I Study of Bromodomain Inhibitor OTX015
This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma.
Charles Ischi Presents Modular Tablet Hardness Tester LAB.line P-Series
Charles Ischi’s versatile laboratory tablet hardness testers in the P-Series offer you the latest technology, space-saving design and maximum flexibility.
Fast Trak Services: A collaborative Project to Accelerate Downstream Biosimilar Process Development
Biosimilars represent an innovative solution to benefit both patients and healthcare systems by reducing the burden of rising treatment costs.
AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).
AAD 2018: AbbVie’s risankizumab boasts strong Phase III data in psoriasis
On February 17th, Phase III head to head clinical trial data assessing the use of AbbVie’s risankizumab in comparison with J&J’s Stelara (ustekinumab) in adult patients with moderate-to-severe chronic plaque psoriasis (PsO) was presented at the 76th Annual American Academy of Dermatology (AAD) meeting.
MESM: Expert Medical Equipment Supplier
When every detail matters and when every second counts, expert support makes the difference. MESM has supplied equipment to nearly 2,000 global trials and hit the SIV date 99.9% of the time.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.